Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decapeptyl plus tamoxifen versus tamoxifen-based standard treatment in premenopausal hormone receptor-positive breast cancer
IRCT20090311001760N47Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Nov 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of triptorelin in breast cancer (2 arms), sponsored by Babol University of Medical Sciences. Primary endpoint: Reduction in local recurrence and distant metastasis of breast cancer in the decapeptyl-receiving group. Started Nov 2011; status: completed.
02
Drugs
triptorelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20090311001760N47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090311001760N47.